Summary of results for the composite primary efficacy end point. The ITT population includes all 26 patients; the completer population includes the 22 patients who completed 52 weeks of treatment. The percentages shown are derived from the corresponding proportions given under each column. The denominator for the 3 component end points equals the number of patients with baseline values that met the study entry criteria for abnormal for that clinical parameter, and the numerator equals the number of these patients who met the criteria for improvement during treatment. For the composite end point, the denominator equals the number of patients in the corresponding analysis population, and the numerator equals the number of these patients who met at least 2 of the 3 component end points.